AU2015236428B2 - TrkA kinase inhibitors, compositions and methods thereof - Google Patents

TrkA kinase inhibitors, compositions and methods thereof Download PDF

Info

Publication number
AU2015236428B2
AU2015236428B2 AU2015236428A AU2015236428A AU2015236428B2 AU 2015236428 B2 AU2015236428 B2 AU 2015236428B2 AU 2015236428 A AU2015236428 A AU 2015236428A AU 2015236428 A AU2015236428 A AU 2015236428A AU 2015236428 B2 AU2015236428 B2 AU 2015236428B2
Authority
AU
Australia
Prior art keywords
methyl
trifluoromethyl
benzamide
pyrazol
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015236428A
Other languages
English (en)
Other versions
AU2015236428A1 (en
Inventor
Kerim Babaoglu
Jianming Bao
Yi-Heng Chen
Andrew J. COOKE
Mark E. Fraley
Chun Sing Li
Ping Liu
Qinghua MAO
Casey C. Mccomas
Melody Mcwherter
Dongfang Meng
Swati P. Mercer
Helen Mitchell
Zhiqi QI
Kathy Schirripa
Craig A. Stump
Harold B. Wood
Jane Wu
Xu-Fang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD R&D China Co Ltd
Merck Sharp and Dohme LLC
Original Assignee
MSD R&D China Co Ltd
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD R&D China Co Ltd, Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical MSD R&D China Co Ltd
Publication of AU2015236428A1 publication Critical patent/AU2015236428A1/en
Application granted granted Critical
Publication of AU2015236428B2 publication Critical patent/AU2015236428B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AU2015236428A 2014-03-26 2015-03-23 TrkA kinase inhibitors, compositions and methods thereof Ceased AU2015236428B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2014/074145 WO2015143654A1 (en) 2014-03-26 2014-03-26 TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
AUPCT/CN2014/074145 2014-03-26
PCT/US2015/021936 WO2015148344A2 (en) 2014-03-26 2015-03-23 Trka kinase inhibitors, compositions and methods thereof

Publications (2)

Publication Number Publication Date
AU2015236428A1 AU2015236428A1 (en) 2016-09-29
AU2015236428B2 true AU2015236428B2 (en) 2018-11-08

Family

ID=54193895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015236428A Ceased AU2015236428B2 (en) 2014-03-26 2015-03-23 TrkA kinase inhibitors, compositions and methods thereof

Country Status (11)

Country Link
US (1) US9815846B2 (cg-RX-API-DMAC7.html)
EP (1) EP3122346B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017512794A (cg-RX-API-DMAC7.html)
KR (1) KR20160128420A (cg-RX-API-DMAC7.html)
CN (1) CN106794161A (cg-RX-API-DMAC7.html)
AU (1) AU2015236428B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016022069A2 (cg-RX-API-DMAC7.html)
CA (1) CA2943858A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016012480A (cg-RX-API-DMAC7.html)
RU (1) RU2672583C2 (cg-RX-API-DMAC7.html)
WO (2) WO2015143654A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
JP6965083B2 (ja) * 2017-10-04 2021-11-10 公益財団法人微生物化学研究会 化合物、及び発光化合物
CN108794414B (zh) * 2018-06-22 2021-01-01 浙江大学 芳酰胺基取代的均三嗪类化合物及制备和应用
CN108997224B (zh) * 2018-08-28 2023-04-28 韶远科技（上海)有限公司 一种2-氯-5-氰基含氮六元杂环化合物的制备方法
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN114401953A (zh) * 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
TW202210467A (zh) * 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
WO2022090101A1 (en) 2020-10-26 2022-05-05 Boehringer Ingelheim International Gmbh Process for synthesis of 2,4-dichloro-5-aminopyrimidine
IL311465A (en) * 2021-09-14 2024-05-01 Univ Vanderbilt Phenyl core compounds as mglu5 negative allosteric modulators and methods of making and using the same
CN113880724A (zh) * 2021-12-06 2022-01-04 南京桦冠生物技术有限公司 一种3-(2-氨基苯基)-2-丙烯酸酯的制备方法
WO2023211256A1 (ko) * 2022-04-29 2023-11-02 제일약품주식회사 신규한 pim 키나아제 억제 화합물 및 이의 용도
WO2024233922A2 (en) * 2023-05-10 2024-11-14 Texas Tech University System Pyridine-piperazine-based scaffolds as highly potent and selective neurolysin activators
WO2024244972A1 (zh) * 2023-05-30 2024-12-05 浙江海正药业股份有限公司 芳香酰胺类衍生物及其制备方法和用途
CN116751115A (zh) * 2023-07-03 2023-09-15 苏州诚和医药化学有限公司 一种间甲氧基氯苄的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103203A1 (en) * 2000-01-21 2002-08-01 Bender Steven Lee Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
EP2151435A1 (en) * 2007-04-24 2010-02-10 Shionogi&Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
WO2013171641A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4638014A (en) * 1985-08-26 1987-01-20 Research Corporation Anticonvulsant method and formulations
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
JP2003506387A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
PL1618092T3 (pl) 2003-05-01 2011-02-28 Bristol Myers Squibb Co Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy
CN102358903B (zh) 2003-07-15 2017-04-26 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
WO2005030128A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
PL1853602T3 (pl) 2005-02-16 2010-11-30 Astrazeneca Ab Związki chemiczne
EP1853610A1 (en) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
EP1877057A1 (en) 2005-04-27 2008-01-16 AstraZeneca AB Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
AU2006278397B2 (en) * 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2007042321A2 (en) 2005-10-13 2007-04-19 Devgen N.V. Kinase inhibitors
EP1959944A1 (en) 2005-12-15 2008-08-27 Shionogi Co., Ltd. A pharmaceutical composition comprising an amide derivative
BRPI0712795A2 (pt) 2006-07-07 2012-09-04 Boehringer Ingelheim Int derivados de heteroarila substituìdos com fenila e uso dos mesmos como agentes antitumorais
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
KR101506750B1 (ko) 2007-04-06 2015-03-27 뉴로크린 바이오사이언시즈 인코퍼레이티드 고나도트로핀-방출 호르몬 수용체 길항제 및 그와 관련된 방법
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
EP2176249A2 (en) 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH New chemical compounds
PL2197849T3 (pl) 2007-10-09 2013-05-31 Merck Patent Gmbh Pochodne n-(pirazolo-3-ylo)-benzamidowe jako aktywatory glukokinazowe
KR20100134693A (ko) * 2008-04-23 2010-12-23 교와 핫꼬 기린 가부시키가이샤 2-아미노퀴나졸린 유도체
EP2272832A4 (en) * 2008-04-28 2011-09-07 Asahi Kasei Pharma Corp PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF
CN102224153B (zh) 2008-09-22 2014-04-30 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物
AU2009300318A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
KR101805754B1 (ko) 2008-12-08 2017-12-07 먼디파머 인터내셔널 코포레이션 리미티드 단백질 수용체 티로신 키나아제 억제제의 조성물
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
JP2013522192A (ja) * 2010-03-11 2013-06-13 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の処置のための化合物
CN102985553B (zh) * 2010-04-15 2015-11-25 西特里斯药业公司 沉默调节蛋白活化剂和活化测定
NZ604831A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
BR112013005070B1 (pt) 2010-09-01 2018-04-03 Bayer Intellectual Property Gmbh Compostos n-(tetrazol-5-il)- e n-(triazol-5-il) arilcarboxamidas, composição herbicida, seus usos como herbicidas e método para controlar plantas indesejadas
WO2012100223A1 (en) 2011-01-21 2012-07-26 John Irwin Synthetic lethal targeting of glucose transport
MX2013009067A (es) * 2011-02-09 2013-10-01 Syngenta Participations Ag Compuestos insecticidas.
AU2012238369A1 (en) * 2011-04-05 2013-10-03 Pfizer Limited Pyrrolo (2, 3 -d) pyrimidine derivatives as inhibitors of tropomyosin- related kinases
BR112013029201B1 (pt) 2011-05-13 2022-08-09 Array Biopharma Inc Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas
SG194107A1 (en) 2011-05-23 2013-11-29 Merck Patent Gmbh Thiazole derivatives
CN102796103A (zh) 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
WO2013176970A1 (en) * 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TW201406736A (zh) * 2012-06-28 2014-02-16 Fujifilm Corp 新穎的醯胺衍生物或其鹽
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
WO2014171464A1 (ja) * 2013-04-15 2014-10-23 株式会社レナサイエンス Ｐａｉ－１阻害剤の新規用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103203A1 (en) * 2000-01-21 2002-08-01 Bender Steven Lee Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
EP2151435A1 (en) * 2007-04-24 2010-02-10 Shionogi&Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
WO2013171641A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SAHU S K ET AL, "Synthesis and biological evaluation of 3-(phthalimidomethyl)-4-(5-substituted isoxazoline and pyrazoline) substituted benzanilides", JOURNAL OF THE INDIAN CHEMICAL SOCIETY,, (2007-10), vol. 84, no. 10, pages 1011 - 1015 *
SÖREN J WACKER ET AL, "The identification of novel, high affinity AQP9 inhibitors in an intracellular binding site", MOLECULAR MEMBRANE BIOLOGY,, (2013), vol. 30, no. 3, pages 246 - 260 *
WEISBERG ET AL, "Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors", THERAPEUTIC DISCOVERY,, (2010-09), vol. 9, no. 9, pages 2468 - 2477 *

Also Published As

Publication number Publication date
AU2015236428A1 (en) 2016-09-29
KR20160128420A (ko) 2016-11-07
EP3122346A4 (en) 2017-08-23
WO2015148344A2 (en) 2015-10-01
CN106794161A (zh) 2017-05-31
EP3122346A2 (en) 2017-02-01
BR112016022069A2 (pt) 2017-08-15
RU2016141646A3 (cg-RX-API-DMAC7.html) 2018-06-26
MX2016012480A (es) 2016-12-20
JP2017512794A (ja) 2017-05-25
RU2672583C2 (ru) 2018-11-16
WO2015143654A8 (en) 2015-12-10
EP3122346B1 (en) 2020-07-15
WO2015143654A1 (en) 2015-10-01
RU2016141646A (ru) 2018-04-27
US20170114071A1 (en) 2017-04-27
WO2015148344A3 (en) 2015-11-26
CA2943858A1 (en) 2015-10-01
US9815846B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
AU2015236428B2 (en) TrkA kinase inhibitors, compositions and methods thereof
EP3122344B1 (en) Trka kinase inhibitors, compositions and methods thereof
US9914736B2 (en) TrKA kinase inhibitors, compositions and methods thereof
CN104254533A (zh) 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
CN104169275A (zh) 用作激酶抑制剂的三唑取代的吡啶化合物
CN104159896A (zh) 用作激酶抑制剂的杂环取代的吡啶基化合物
CA2681516A1 (en) Compounds useful as inhibitors of janus kinases
JP2018506571A (ja) Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
IL285246B1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
WO2016054807A1 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2016164286A2 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9102673B2 (en) Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired